Ohio State Navbar


David M. Lucas, PhD

Staff photo

320 W 10th Ave
Room A350B
Columbus, OH 43210

Phone: (614) 685-5667

Email: lucas.194@osu.edu


Current OSU Appointment

Research Assistant Professor, Hematology


Academic Advising

2011 Yo-Ting Tsai, The Ohio State University. Graduated 0.
2011 John Patton, The Ohio State University. Graduated 2016.
2013 John Woodard, The Ohio State University. Graduated 0.
2014 Porsha Smith, The Ohio State University. Graduated 0.
2015 Aparna Lakshmanan, The Ohio State University. Graduated 0.
2000 Michael Barnes, The Ohio State University. Graduated 0.
2004 Benjamin Lampson, The Ohio State University. Graduated 0.
2007 - 2009 Yanhui Lu, The Ohio State University. Graduated 0.
2009 David Caldwell, The Ohio State University. Graduated 0.
2010 James Hall, The Ohio State University. Graduated 0.
2012 Jennie Rowell, The Ohio State University. Graduated 0.
2013 Kim Seoungbum, The Ohio State University. Graduated 0.
2014 Jason Parker, The Ohio State University. Graduated 0.
2016 - 2014 Allahna Esber, The Ohio State University. Graduated 0.
2015 Max Yano, The Ohio State University. Graduated 0.
2015 Colleen Baker, The Ohio State University. Graduated 0.
2015 Joseph Long, The Ohio State University. Graduated 0.


1991 B.A., Miami University of Ohio

1996 Ph.D., University of Wisconsin

2000 None Indicated, Fred Hutchinson Cancer Research Center


Editorial Activities

2006 - present Leukemia Research
2006 - present Leukemia & Lymphoma
2006 - present Journal of Clinical Oncology
2006 - present Journal of Natural Products
2006 - present Blood
2006 - present Haematologica


1987 - present Ben Suffron Memorial Scholarship.
1987 - 1991 Miami Alumni Merit Scholarship. Miami Alumni Merit Scholarship.
1987 - 1991 National Merit Scholarship. National Merit Scholarship.
1990 - present Harvey Clayton Brill Scholarship.
1991 - present Wisconsin Alumni Research Foundation Fellowship.
1992 - 1995 Training Grant in Molecular Biology. National Institutes of Health.
1994 - present Presidential Awards Competition. Society of Leukocyte Biology.
1997 - 2000 National Research Service Award. F32, National Institutes of Health.
2004 - present V-Foundation-AACR Translational Grant Award Co-Investigator.
2007 - present American Cancer Society Institutional Seed Grant Recipient.
2011 - 2012 Pelotonia Idea Award. Pelotonia.

Journal Articles

McDowell,M,A; Lucas,D,M; Nicolet,C,M; Paulnock,D,M. "Differential utilization of IFN-gamma-responsive elements in two maturationally distinct macrophage cell lines.." Journal Of Immunology (Baltimore, Md.: 1950). Vol. 155, no. 10. (November 1995.): 4933-.

Lucas,D,M; Lokuta,M,A; McDowell,M,A; Doan,J,ES; Paulnock,D,M. "Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation.." Journal Of Immunology (Baltimore, Md.: 1950). Vol. 160, no. 9. (May 1998.): 4337-.

Lucas,D,M; Rohrschneider,L,R. "A novel spliced form of SH2-containing inositol phosphatase is expressed during myeloid development.." Blood. Vol. 93, no. 6. (March 1999.): 1922-.

Wolf,I; Lucas,D,M; Algate,P,A; Rohrschneider,L,R. "Cloning of the genomic locus of mouse SH2 containing inositol 5-phosphatase (SHIP) and a novel 110-kDa splice isoform, SHIPdelta.." Genomics. Vol. 69, no. 1. (October 2000.): 104-.

March,M,E; Lucas,D,M; Aman,M,J; Ravichandran,K,S. "p135 src homology 2 domain-containing inositol 5'-phosphatase (SHIPbeta ) isoform can substitute for p145 SHIP in fcgamma RIIB1-mediated inhibitory signaling in B cells.." The Journal Of Biological Chemistry. Vol. 275, no. 39. (September 2000.): 29960-.

Rohrschneider,L,R; Fuller,J,F; Wolf,I; Liu,Y; Lucas,D,M. "Structure, function, and biology of SHIP proteins.." Genes & Development. Vol. 14, no. 5. (March 2000.): 505-.

Byrd,J,C; Shinn,C; Willis,C,R; Flinn,I,W; Lehman,T; Suasville,E; Lucas,D; Gerver,M,R. "UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism." Exp Hematol. Vol. 29, no. 6. (January 2001.): 703-8.

Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas DM, Reed JC. "The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction." Blood. Vol. 3, no. 99. (January 2002.): 1038-1043.

Pavletic,S,Z; Bociek,R,G; Foran,J,M; Rubocki,R,J; Kuszynski,C,A; Wisecarver,J,L; Hatcher,L; Lucas,D,M; Byrd,J,C; Grever,M,R; Joshi,S,S; Hardiman,P; Smith,L,M; McGuire,T,R; Bierman,P,J; Vose,J,M; Armitage,J,O; Talmadge,J,E. "Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation.." Transplantation. Vol. 76, no. 5. (September 2003.): 877-.

Bains,S,K; Mone,A; Tso,J,Y; Lucas,D; Byrd,J,C; Weiner,G,J; Green,J,M. "Mitochondria control of cell death induced by anti-HLA-DR antibodies." Leukemia. Vol. 17, no. 7. (January 2003.): 1357-1365.

Marcucci,G; Byrd,J,C; Dai,G,W; Klisovic,M,I; Kourlas,P,J; Young,D,C; Cataland,S,R; Fisher,D,B; Lucas,D; Chan,K,K; Porcu,P; Lin,Z,P; Farag,S,F; Frankel,S,R; Zvviebel,J,A; Kraut,E,H; Balcerzak,S,P; Bloomfield,C,D; Grever,M,R; Caligiuri,M,A. "Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia." Blood. Vol. 101, no. 2. (January 2003.): 425-32.

Byrd,J,C; Lucas,D,M; Mone,A,P; Kitner,J,B; Drabick,J,J; Grever,M,R. "KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis.." Blood. Vol. 101, no. 11. (June 2003.): 4547-.

Aron,J,L; Parthun,M,R; Marcucci,G; Kitada,S; Mone,A,P; Davis,M,E; Shen,T,S; Murphy,T; Wickham,J; Kanakry,C; Lucas,D,M; Reed,J,C; Grever,M,R; Byrd,J,C. "Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.." Blood. Vol. 102, no. 2. (July 2003.): 652-.

Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas DM, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC. "G3139, a BCL-2 antisense oligo-nucleotide, in AML.." Ann Hematol. Vol. 83, (January 2004.): 93-4.

Rush,L,J; Raval,A; Funchain,P; Johnson,A,J; Smith,L; Lucas,D,M; Bembea,M; Liu,T,H; Heerema,N,A; Rassenti,L; Liyanarachchi,S; Davuluri,R; Byrd,J,C; Plass,C. "Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets.." Cancer Research. Vol. 64, no. 7. (April 2004.): 2424-.

Lozanski,G; Heerema,N,A; Flinn,I,W; Smith,L; Harbison,J; Webb,J; Moran,M; Lucas,M; Lin,T; Hackbarth,M,L; Proffitt,J,H; Lucas,D; Grever,M,R; Byrd,J,C. "Alemtuzumab is an Effective Therapy for Chronic Lymphocytic Leukemia with p53 Mutations and Deletions." Blood. Vol. 103, no. 9. (January 2004.): 3278-81.

Lucas,D,M; Davis,M,E; Parthun,M,R; Mone,A,P; Kitada,S; Cunningham,K,D; Flax,E,L; Wickham,J; Reed,J,C; Byrd,J,C; Grever,M,R. "The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 18, no. 7. (July 2004.): 1207-.

Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC. "Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 19, no. 7. (July 2005.): 1207-.

Byrd,J,C; Marcucci,G; Parthun,M,R; Xiao,J,J; Klisovic,R,B; Moran,M; Lin,T,S; Liu,S,J; Sklenar,A,R; Davis,M,E; Lucas,D,M; Fischer,B; Shank,R; Tejaswi,S,L; Binkley,P; Wright,J; Chan,K,K; Grever,M,R. "A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.." Blood. Vol. 105, no. 3. (February 2005.): 959-.

Bolanos-Meade,J; Jacobsohn,D,A; Margolis,J; Ogden,A; Wientjes,M,G; Byrd,J,C; Lucas,D,M; Anders,V; Phelps,M; Grever,M,R; Vogelsang,G,B. "Pentostatin in steroid-refractory acute graft-versus-host disease.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 23, no. 12. (April 2005.): 2661-.

Raval,A; Lucas,D,M; Matkovic,J,J; Bennett,K,L; Liyanarachchi,S; Young,D,C; Rassenti,L; Kipps,T,J; Grever,M,R; Byrd,J,C; Plass,C. "TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 23, no. 17. (June 2005.): 3877-.

Byrd,J,C; Gribben,J,G; Peterson,B,L; Grever,M,R; Lozanski,G; Lucas,D,M; Lampson,B; Larson,R,A; Caligiuri,M,A; Heerema,N,A. "Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 24, no. 3. (January 2006.): 437-.

Johnson,Amy,J; Lucas,David,M; Muthusamy,Natarajan; Smith,Lisa,L; Edwards,Ryan,B; De lay,Michael,D; Croce,Carlo,M; Grever,Michael,R; Byrd,John,C. "Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.." Blood. Vol. 108, no. 4. (August 2006.): 1334-.

Byrd,John,C; Lin,Thomas,S; Dalton,James,T; Wu,Di; Phelps,Mitch,A; Fischer,Beth; Moran,Mollie; Blum,Kristie,A; Rovin,Brad; Brooker-McEldowney,Michelle; Broering,Sarah; Schaaf,Larry,J; Johnson,Amy,J; Lucas,David,M; Heerema,Nyla,A; Lozanski,Gerard; Young,Donn,C; Suarez,Jose-Ramon; Colevas,A,Dimitrios; Grever,Michael,R. "Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.." Blood. Vol. 109, no. 2. (January 2007.): 399-.

Johnson,Amy,J; Wagner,Amy,J; Cheney,Carolyn,M; Smith,Lisa,L; Lucas,David,M; Guster,Sara,K; Grever,Michael,R; Lin,Thomas,S; Byrd,John,C. "Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.." British Journal Of Haematology. Vol. 139, no. 5. (December 2007.): 837-.

Grever,Michael,R; Lucas,David,M; Johnson,Amy,J; Byrd,John,C. "Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia.." Best Practice & Research. Clinical Haematology. Vol. 20, no. 3. (September 2007.): 545-.

Su,Xiaodan; Jacob,Naduparambil,K; Amunugama,Ravindra; Lucas,David,M; Knapp,Amy,R; Ren,Chen; Davis,Melanie,E; Marcucci,Guido; Parthun,Mark,R; Byrd,John,C; Fishel,Richard; Freitas,Michael,A. "Liquid chromatography mass spectrometry profiling of histones.." Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences. Vol. 850, no. 1-2. (May 2007.): 440-.

Grever,Michael,R; Lucas,David,M; Dewald,Gordon,W; Arenberg,Donna,S; Reed,John,C; Kitada,Shinichi; Flinn,Ian,W; Tallman,Martin,S; Appelbaum,Frederick,R; Larson,Richard,A; Paietta,Elisabeth; Jelinek,Diane,F; Gribben,John,G; Byrd,John,C. "Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 25, no. 7. (March 2007.): 799-.

Su,Xiaodan; Zhang,Liwen; Lucas,David,M; Davis,Melanie,E; Knapp,Amy,R; Green-Church,Kari,B; Marcucci,Guido; Parthun,Mark,R; Byrd,John,C; Freitas,Michael,A. "Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry.." Analytical Biochemistry. Vol. 363, no. 1. (April 2007.): 22-.

Knapp,Amy,R; Ren,Chen; Su,Xiaodan; Lucas,David,M; Byrd,John,C; Freitas,Michael,A; Parthun,Mark,R. "Quantitative profiling of histone post-translational modifications by stable isotope labeling.." Methods (San Diego, Calif.). Vol. 41, no. 3. (March 2007.): 312-.

Raval,Aparna; Tanner,Stephan,M; Byrd,John,C; Angerman,Elizabeth,B; Perko,James,D; Chen,Shih-Shih; Hackanson,Bjoern; Grever,Michael,R; Lucas,David,M; MatkoviC,Jennifer,J; Lin,Thomas,S; Kipps,Thomas,J; Murray,Fiona; Weisenburger,Dennis; Sanger,Warren; Lynch,Jane; Watson,Patrice; Jansen,Mary; Yoshinaga,Yuko; Rosenquist,Richard; de Jong,Pieter,J; Coggill,Penny; Beck,Stephan; Lynch,Henry; de la Chapelle,Albert; Plass,Christoph. "Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.." Cell. Vol. 129, no. 5. (June 2007.): 879-.

Motiwala,Tasneem; Majumder,Sarmila; Kutay,Huban; Smith,David,Spencer; Neuberg,Donna,S; Lucas,David,M; Byrd,John,C; Grever,Michael; Jacob,Samson,T. "Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 11. (June 2007.): 3174-.

Hussain,Syed-Rehan,A; Cheney,Carolyn,M; Johnson,Amy,J; Lin,Thomas,S; Grever,Michael,R; Caligiuri,Michael,A; Lucas,David,M; Byrd,John,C. "Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 7. (April 2007.): 2144-.

Berdeja,Jesus,G; Hess,Allan; Lucas,David,M; O'Donnell,Paul; Ambinder,Richard,F; Diehl,Louis,F; Carter-Brookins,Denise; Newton,Susan; Flinn,Ian,W. "Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.." Clinical Cancer Research: An Official Journal Of The American Association For Cancer Research. Vol. 13, no. 8. (April 2007.): 2392-.

Browning,Rebekah,L; Geyer,Susan,M; Johnson,Amy,J; Jelinek,Diane,E; Tschumper,Renee,C; Call,Timothy,G; Shanafelt,Tait,D; Zent,Clive,S; Bone,Nancy,D; Dewald,Gordon,W; Lin,Thomas,S; Heerema,Nyla,A; Grever,Michael,R; Kay,Neil,E; Byrd,John,C; Lucas,David,M. "Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia.." Leukemia Research. Vol. 31, no. 12. (December 2007.): 1737-.

Lucas DM; Byrd JC. "Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.." Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology. Vol. 26, no. 14. (May 2008.): 2244-.

Hussain,Syed-Rehan,A; Lucas,David,M; Johnson,Amy,J; Lin,Thomas,S; Bakaletz,Alan,P; Dang,Vinh,X; Viatchenko-Karpinski,Serge; Ruppert,Amy,S; Byrd,John,C; Kuppusamy,Periannan; Crouser,Elliott,D; Grever,Michael,R. "Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium.." Blood. Vol. 111, no. 6. (March 2008.): 3190-.

Blum,Kristie,A; Hamadani,Mehdi; Phillips,Gary,S; Lozanski,Gerard; Johnson,Amy,J; Lucas,David,M; Smith,Lisa,L; Baiocchi,Robert; Lin,Thomas,S; Porcu,Pierluigi; Devine,Steven,M; Byrd,John,C. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma." LEUKEMIA & LYMPHOMA. Vol. 50, no. 7. (January 2009.): 1232-1234.

Lucas,David,M; Edwards,Ryan,B; Lozanski,Gerard; West,Derek,A; Shin,Jungook,D; Vargo,Melissa,A; Davis,Melanie,E; Rozewski,Darlene,M; Johnson,Amy,J; Su,Bao-Ning; Goettl,Virginia,M; Heerema,Nyla,A; Lin,Thomas,S; Lehman,Amy; Zhang,Xiaoli; Jarjoura,David; Newman,David,J; Byrd,John,C; Kinghorn,A,Douglas; Grever,Michael,R. "The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.." Blood. Vol. 113, no. 19. (May 2009.): 4656-.

Lin,Thomas,S; Naumovski,Louie; Lecane,Philip,S; Lucas,Margaret,S; Moran,Mollie,E; Cheney,Carolyn; Lucas,David,M; Phan,See-Chun; Miller,Richard,A; Byrd,John,C. "Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.." Leukemia & Lymphoma. Vol. 50, no. 12. (December 2009.): 1977-.

Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST. "PTPROt Inactivates the Oncogenic Fusion Protein BCR/ABL and Suppresses Transformation of K562 Cells." J Biol Chem. (January 2009.): -.

Woyach,J,A; Lin,T,S; LUCAS,M,S; Heerema,N; Moran,M,E; Cheney,C; Lucas,D,M; Wei,L; Caligiuri,M,A; Byrd,J,C. "A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 23, no. 5. (May 2009.): 912-.

Blum KA, Advani A, Fernandez L, van der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell, R, Byrd JC.. "Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.." British Journal Of Haematology. Vol. 147, no. 4. (November 2009.): 507-.

Blum,Kristie,A; Hamadani,Mehdi; Phillips,Gary,S; Lozanski,Gerard; Johnson,Amy,J; Lucas,David,M; Smith,Lisa,L; Baiocchi,Robert; Lin,Thomas,S; Porcu,Pierluigi; Devine,Steven,M; Byrd,John,C. "Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma.." Leukemia & Lymphoma. Vol. 50, no. 3. (March 2009.): 349-.

Awan,Farrukh,T; Kay,Neil,E; Davis,Melanie,E; Wu,Wenting; Geyer,Susan,M; Leung,Nelson; Jelinek,Diane,F; Tschumper,Renee,C; Secreto,Charla,R; Lin,Thomas,S; Grever,Michael,R; Shanafelt,Tait,D; Zent,Clive,S; Call,Timothy,G; Heerema,Nyla,A; Lozanski,Gerard; Byrd,John,C; Lucas,David,M. "Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.." Blood. Vol. 113, no. 3. (January 2009.): 535-.

Alinari,Lapo; White,Valerie,L; Earl,Christian,T; Ryan,Timothy,P; Johnston,Jeffrey,S; Dalton,James,T; Ferketich,Amy,K; Lai,Raymond; Lucas,David,M; Porcu,Pierluigi; Blum,Kristie,A; Byrd,John,C; Baiocchi,Robert,A. "Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.." Mabs. Vol. 1, no. 1. (January 2009.): 31-.

Su,Xiaodan; Lucas,David,M; Zhang,Liwen; Xu,Hua; Zabrouskov,Vlad; Davis,Melanie,E; Knapp,Amy,R; Young,Donn,C; Payne,Philip,RO; Parthun,Mark,R; Marcucci,Guido; Grever,Michael,R; Byrd,John,C; Freitas,MichaelA. "Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia.." Proteomics. Vol. 9, no. 5. (March 2009.): 1197-.

Sanchez-Aguilera,A; Rattmann,I; Drew,D,Z; Mueller,L,UW; Summey,V; Lucas,D,M; Byrd,J,C; Croce,C,M; Gu,Y; Cancelas,J,A; Johnston,P; Moritz,T; Williams,D,A. "Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia.." Leukemia: Official Journal Of The Leukemia Society Of America, Leukemia Research Fund, U.K. Vol. 24, no. 1. (January 2010.): 97-.

Lucas, DM, Still PC, Pérez LB, Grever MR, Kinghorn AD. Curr Drug Targets. Vol. 11, no. 7. (July 2010.): 812-822.

Blum,K,A; Jung,S-H; Johnson,J,L; Lin,T,S; Hsi,E,D; Lucas,D,M; Byrd,J,C; Cheson,B,D; Bartlett,N,L. "Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.." Annals Of Oncology: Official Journal Of The European Society For Medical Oncology / ESMO. Vol. 21, no. 11. (November 2010.): 2246-.

Blum,Kristie,A; Liu,Zhongfa; Lucas,David,M; Chen,Ping; Xie,Zhiliang; Baiocchi,Robert; Benson,Donald,M; Devine,Steven,M; Jones,Jeffrey; Andritsos,Leslie; Flynn,Joseph; Plass,Christoph; Marcucci,Guido; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.." British Journal Of Haematology. Vol. 150, no. 2. (July 2010.): 189-.

Lucas,David,M; Still,Patrick,C; Perez,Lynette,Bueno; Grever,Michael,R; Kinghorn,A,Douglas. "Potential of plant-derived natural products in the treatment of leukemia and lymphoma.." Current Drug Targets. Vol. 11, no. 7. (July 2010.): 812-.

Blum KA, Jund S-H, Johnson L, Lin Ts, Hsi Ed,Lucas, DM, Byrd JC, Cheson N, Bartlett L and for the Cancer and Leukemia Group B. "Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcRIIIa-158 V/F polymorphism." Annals of Oncology. (April 2010.): -.

Hertlein,Erin; Triantafillou,Georgia; Sass,Ellen,J; Hessler,Joshua,D; Zhang,Xiaoli; Jarjoura,David; Lucas,David,M; Muthusamy,Natarajan; Goldenberg,David,M; Lee,Robert,J; Byrd,John,C. "Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells.." Blood. Vol. 116, no. 14. (October 2010.): 2554-.

Ramaswamy,Bhuvaneswari; Bekaii-Saab,Tanios; Schaaf,Larry,J; Lesinski,Gregory,B; Lucas,David,M; Young,Donn,C; Ruppert,Amy,S; Byrd,John,C; Culler,Kristy; Wilkins,Diedre; Wright,John,J; Grever,Michael,R; Shapiro,Charles,L. "A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.." Cancer Chemotherapy And Pharmacology. Vol. 66, no. 1. (May 2010.): 151-.

Lucas,David,M; Alinari,Lapo; West,Derek,A; Davis,Melanie,E; Edwards,Ryan,B; Johnson,Amy,J; Blum,Kristie,A; Hofmeister,Craig,C; Freitas,Michael,A; Parthun,Mark,R; Wang,Dasheng; Lehman,Amy; Zhang,Xiaoli; Jarjoura,David; Kulp,Samuel,K; Croce,Carlo,M; Grever,Michael,R; Chen,Ching-Shih; Baiocchi,Robert,A; Byrd,John,C. "The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo.." Plos One. Vol. 5, no. 6. (June 2010.): e10941-.

Flynn,Joseph,M; Andritsos,Leslie; Lucas,David; Byrd,John,C. "Second malignancies in C-cell chromic lymphocytic leukemia: possible association with human papilloma virus." British Journal of Haematology. Vol. 3, no. 149. (January 2010.): 388-390.

Blum,William; Phelps,Mitch,A; Klisovic,Rebecca,B; Rozewski,Darlene,M; Ni,Wenjun; Albanese,Katie,A; Rovin,Brad; Kefauver,Cheryl; Devine,Steven,M; Lucas,David,M; Johnson,Amy; Schaaf,Larry,J; Byrd,John,C; Marcucci,Guido; Greyer,Michael,R. "Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.." Haematologica. Vol. 95, no. 7. (July 2010.): 1098-.

Motiwala,Tasneem; Zanesi,Nicola; Datta,Jharna; Roy,Satavisha; Kutay,Huban; Checovich,Allyn,M; Kaou,Mohamed; Zhong,Yiming; Johnson,Amy,J; Lucas,David,M; Heerema,Nyla,A; Hagan,John; Mo,Xiaokui; Jarjoura,David; Byrd,John,C; Croce,Carlo,M; Jacob,Samson,T. "AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia.." Blood. Vol. 118, no. 23. (December 2011.): 6132-.

Chen,Shih-Shih; Claus,Rainer; Lucas,David,M; Yu,Lianbo; Qian,Jiang; Ruppert,Amy,S; West,Derek,A; Williams,Katie,E; Johnson,Amy,J; Sablitzky,Fred; Plass,Christoph; Byrd,John,C. "Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.." Blood. Vol. 117, no. 3. (January 2011.): 862-.

Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Pan L, Chan KK, Kinghorn AD, Phelps MA, Grever MR, Lucas, DM. "Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells.." AAPS. no. Epub ahead of print. (May 2011.): -.

Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas, DM, Grever MR, Phelps MA, Chan KK.. "Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography-Tandem Mass Spectrometry." AAPS. no. Epub ahead of print. (April 2011.): -.

Saradhi,U,VRVijaya; Gupta,Sneha,V; Chiu,Ming; Wang,Jiang; Ling,Yonghua; Liu,Zhongfa; Newman,David,J; Covey,Joseph,M; Kinghorn,A,Douglas; Marcucci,Guido; Lucas,David,M; Grever,Michael,R; Phelps,Mitch,A; Chan,Kenneth,K. "Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry.." The AAPS Journal. Vol. 13, no. 3. (September 2011.): 347-.

You,Jia; Wang,Liwen; Saji,Motoyasu; Olesik,Susan,V; Ringel,Matthew,D; Lucas,David,M; Byrd,John,C; Freitas,Michael,A. "High-sensitivity TFA-free LC-MS for profiling histones.." Proteomics. Vol. 11, no. 16. (August 2011.): 3326-.

Gupta,Sneha,V; Sass,Ellen,J; Davis,Melanie,E; Edwards,Ryan,B; Lozanski,Gerard; Heerema,Nyla,A; Lehman,Amy; Zhang,Xiaoli; Jarjoura,David; Byrd,John,C; Pan,Li; Chan,Kenneth,K; Kinghorn,A,Douglas; Phelps,Mitch,A; Grever,Michael,R; Lucas,David,M. "Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.." The AAPS Journal. Vol. 13, no. 3. (September 2011.): 357-.

Mahoney,Emilia; Lucas,David,M; Gupta,Sneha,V; Wagner,Amy,J; Herman,Sarah,EM; Smith,Lisa,L; Yeh,Yuh-Ying; Andritsos,Leslie; Jones,Jeffrey,A; Flynn,Joseph,M; Blum,Kristie,A; Zhang,Xiaoli; Lehman,Amy; Kong,Hui; Gurcan,Metin; Grever,Michael,R; Johnson,Amy,J; Byrd,John,C. "ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol." BLOOD. Vol. 120, no. 6. (August 2012.): 1262-1273.

Lozanski,Gerard; Ruppert,Amy,S; Heerema,Nyla,A; Lozanski,Arletta; Lucas,David,M; Gordon,Amber; Gribben,John,G; Morrison,Vicki,A; Rai,Kanti,M; Marcucci,Guido; Larson,Richard,A; Byrd,John,C. "Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study." LEUKEMIA & LYMPHOMA. Vol. 53, no. 9. (September 2012.): 1743-1748.

Alinari,Lapo; Prince,Courtney,J; Edwards,Ryan,B; Towns,William,H; Mani,Rajeswaran; Lehman,Amy; Zhang,Xiaoli; Jarjoura,David; Pan,Li; Kinghorn,A,Douglas; Grever,Michael,R; Baiocchi,Robert,A; Lucas,David,M. "Dual Targeting of the Cyclin/Rb/E2F and Mitochondrial Pathways in Mantle Cell Lymphoma with the Translation Inhibitor Silvestrol." CLINICAL CANCER RESEARCH. Vol. 18, no. 17. (September 2012.): 4600-4611.

Claus,Rainer; Lucas,David,M; Stilgenbauer,Stephan; Ruppert,Amy,S; Yu,Lianbo; Zucknick,Manuela; Mertens,Daniel; Buehler,Andreas; Oakes,Christopher,C; Larson,Richard,A; Kay,Neil,E; Jelinek,Diane,F; Kipps,Thomas,J; Rassenti,Laura,Z; Gribben,John,G; Doehner,Hartmut; Heerema,Nyla,A; Marcucci,Guido; Plass,Christoph; Byrd,John,C. "Quantitative DNA Methylation Analysis Identifies a Single CpG Dinucleotide Important for ZAP-70 Expression and Predictive of Prognosis in Chronic Lymphocytic Leukemia." JOURNAL OF CLINICAL ONCOLOGY. Vol. 30, no. 20. (July 2012.): 2483-2491.

Lapalombella,Rosa; Yeh,Yuh-Ying; Wang,Liwen; Ramanunni,Asha; Rafiq,Sarwish; Jha,Shruti; Staubli,Justin; Lucas,David,M; Mani,Rajeswaran; Herman,Sarah,EM; Johnson,Amy,J; Lozanski,Arletta; Andritsos,Leslie; Jones,Jeffrey; Flynn,Joseph,M; Lannutti,Brian; Thompson,Peter; Algate,Paul; Stromatt,Scott; Jarjoura,David; Mo,Xiaokui; Wang,Dasheng; Chen,Ching-Shih; Lozanski,Gerard; Heerema,Nyla,A; Tridandapani,Susheela; Freitas,Michael,A; Muthusamy,Natarajan; Byrd,John,C. "Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals." CANCER CELL. Vol. 21, no. 5. (May 2012.): 694-708.

Lapalombella,Rosa; Sun,Qingxiang; Williams,Katie; Tangeman,Larissa; Jha,Shruti; Zhong,Yiming; Goettl,Virginia; Mahoney,Emilia; Berglund,Caroline; Gupta,Sneha; Farmer,Alicia; Mani,Rajeswaran; Johnson,Amy,J; Lucas,David; Mo,Xiaokui; Daelemans,Dirk; Sandanayaka,Vincent; Shechter,Sharon; McCauley,Dilara; Shacham,Sharon; Kauffman,Michael; Chook,Yuh,Min; Byrd,John,C. "Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia." BLOOD. Vol. 120, no. 23. (November 2012.): 4621-4634.

Alachkar,Houda; Santhanam,Ramasamy; Harb,Jason,G; Lucas,David,M; Oaks,Joshua,J; Hickey,Christopher,J; Pan,Li; Kinghorn,A,Douglas; Caligiuri,Michael,A; Perrotti,Danilo; Byrd,John,C; Garzon,Ramiro; Grever,Michael,R; Marcucci,Guido. "Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia." JOURNAL OF HEMATOLOGY & ONCOLOGY. Vol. 6, (March 2013.): 21-.

Gupta,Sneha,V; Hertlein,Erin; Lu,Yanhui; Sass,Ellen,J; Lapalombella,Rosa; Chen,Timothy,L; Davis,Melanie,E; Woyach,Jennifer,A; Lehman,Amy; Jarjoura,David; Byrd,John,C; Lucas,David,M. "The Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Cytotoxicity and an Atypical NF-kappa B Response in Chronic Lymphocytic Leukemia Cells." CLINICAL CANCER RESEARCH. Vol. 19, no. 9. (May 2013.): 2406-2419.

Kogure,Takayuki; Kinghorn,A,Douglas; Yan,Irene; Bolon,Brad; Lucas,David,M; Grever,Michael,R; Patel,Tushar. "Therapeutic Potential of the Translation Inhibitor Silvestrol in Hepatocellular Cancer." PLOS ONE. Vol. 8, no. 9. (September 2013.): e76136-.

Perez,Lynette,Bueno; Li,Jie; Lantvit,Daniel,D; Pan,Li; Tran Ngoc Ninh,T,N; Chai,Hee-Byung; Soejarto,Djaja,Djendoel; Swanson,Steven,M; Lucas,David,M; Kinghorn,A,Douglas. "Bioactive Constituents of Indigofera spicata." JOURNAL OF NATURAL PRODUCTS. Vol. 76, no. 8. (August 2013.): 1498-1504.

Perez,Lynette,Bueno; Pan,Li; Sass,Ellen; Gupta,Sneha,V; Lehman,Amy; Kinghorn,A,Douglas; Lucas,David,M. "Potentiating Effect of the Flavonolignan (-)-Hydnocarpin in Combination with Vincristine in a Sensitive and P-gp-Expressing Acute Lymphoblastic Leukemia Cell Line." PHYTOTHERAPY RESEARCH. Vol. 27, no. 11. (November 2013.): 1735-1738.

Poi,Ming,J; Hofmeister,Craig,C; Johnston,Jeffrey,S; Edwards,Ryan,B; Jansak,Buffy,S; Lucas,David,M; Farag,Sherif,S; Dalton,James,T; Devine,Steven,M; Grever,Michael,R; Phelps,Mitch,A. "Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease." CLINICAL PHARMACOKINETICS. Vol. 52, no. 8. (August 2013.): 705-712.

Singh,Rajbir; Mortazavi,Amir; Telu,Kelly,H; Nagarajan,Prabakaran; Lucas,David,M; Thomas-Ahner,Jennifer,M; Clinton,Steven,K; Byrd,John,C; Freitas,Michael,A; Parthun,Mark,R. "Increasing the complexity of chromatin: functionally distinct roles for replication-dependent histone H2A isoforms in cell proliferation and carcinogenesis." NUCLEIC ACIDS RESEARCH. Vol. 41, no. 20. (November 2013.): 9284-9295.

Woyach,Jennifer,A; Smucker,Kelly; Smith,Lisa,L; Lozanski,Arletta; Zhong,Yiming; Ruppert,Amy,S; Lucas,David; Williams,Katie; Zhao,Weiqiang; Rassenti,Laura; Ghia,Emanuela; Kipps,Thomas,J; Mantel,Rose; Jones,Jeffrey; Flynn,Joseph; Maddocks,Kami; O'Brien,Susan; Furman,Richard,R; James,Danelle,F; Clow,Fong; Lozanski,Gerard; Johnson,Amy,J; Byrd,John,C. "Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy." BLOOD. Vol. 123, no. 12. (March 2014.): 1810-1817.

Claus,Rainer; Lucas,David,M; Ruppert,Amy,S; Williams,Katie,E; Weng,Daniel; Patterson,Kara; Zucknick,Manuela; Oakes,Christopher,C; Rassenti,Laura,Z; Greaves,Andrew,W; Geyer,Susan; Wierda,William,G; Brown,Jennifer,R; Gribben,John,G; Barrientos,Jacqueline,C; Rai,Kanti,R; Kay,Neil,E; Kipps,Thomas,J; Shields,Peter; Zhao,Weiqiang; Grever,Michael,R; Plass,Christoph; Byrd,John,C. "Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia." BLOOD. Vol. 124, no. 1. (July 2014.): 42-48.

Nicolau,Hugo; Guerreiro,Tiago; Lucas,David; Jorge,Joaquim. "Mobile text-entry and visual demands: reusing and optimizing current solutions." UNIVERSAL ACCESS IN THE INFORMATION SOCIETY. Vol. 13, no. 3. (August 2014.): 291-301.

Callahan,K,P; Minhajuddin,M; Corbett,C; Lagadinou,E,D; Rossi,R,M; Grose,V; Balys,M,M; Pan,L; Jacob,S; Frontier,A; Grever,M,R; Lucas,D,M; Kinghorn,A,D; Liesveld,J,L; Becker,M,W; Jordan,C,T. "Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity." LEUKEMIA. Vol. 28, no. 10. (October 2014.): 1960-1968.

Tsai,Yo-Ting; Lozanski,Gerard; Lehman,Amy; Sass,Ellen,J; Hertlein,Erin; Salunke,Santosh,B; Chen,Ching-Shih; Grever,Michael,R; Byrd,John,C; Lucas,David,M. "BRAF(V600E) induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation." LEUKEMIA RESEARCH. Vol. 39, no. 11. (November 2015.): 1270-1277.

El-Elimat,Tamam; Raja,Huzefa,A; Figueroa,Mario; Swanson,Steven,M; Falkinham,Joseph,O; Lucas,David,M; Grever,Michael,R; Wani,Mansukh,C; Pearce,Cedric,J; Oberlies,Nicholas,H. "Sorbicillinoid analogs with cytotoxic and selective anti-Aspergillus activities from Scytalidium album." JOURNAL OF ANTIBIOTICS. Vol. 68, no. 3. (March 2015.): 191-196.

Blachly,James,S; Lozanski,Gerard; Lucas,David,M; Grever,Michael,R; Kendra,Kari; Andritsos,Leslie,A. "Cotreatment of Hairy Cell Leukemia and Melanoma With the BRAF Inhibitor Dabrafenib." JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK. Vol. 13, no. 1. (January 2015.): 9-13.

Patton,John,T; Lustberg,Mark,E; Lozanski,Gerard; Garman,Sabrina,L; Towns,William,H; Drohan,Callie,M; Lehman,Amy; Zhang,Xiaoli; Bolon,Brad; Pan,Li; Kinghorn,A,Douglas; Grever,Michael,R; Lucas,David,M; Baiocchi,Robert,A. "The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease." ONCOTARGET. Vol. 6, no. 5. (February 2015.): 2693-2708.

Singh R, Harshman SW, Ruppert AS, Mortazavi A, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MR. "Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.." Clinical proteomics. Vol. 12, no. 1. (January 2015.): 22-?.

Lucas,David,M; Ruppert,Amy,S; Lozanski,Gerard; Dewald,Gordon,W; Lozanski,Arletta; Claus,Rainer; Plass,Christoph; Flinn,Ian,W; Neuberg,Donna,S; Paietta,Elisabeth,M; Bennett,John,M; Jelinek,Diane,F; Gribben,John,G; Hussein,Mohamad,A; Appelbaum,Frederick,R; Larson,Richard,A; Moore,Dennis,F; Tallman,Martin,S; Byrd,John,C; Grever,Michael,R. "Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997." LEUKEMIA & LYMPHOMA. Vol. 56, no. 11. (November 2015.): 3031-3037.

Andritsos,Leslie,A; Dunavin,Neil; Lozanski,Gerard; Jones,Jeffrey,A; Blachly,James,S; Lucas,David,M; Byrd,John,C; Kraut,Eric; Grever,Michael,R. "Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective." HAEMATOLOGICA. Vol. 100, no. 1. (January 2015.): E18-E20.

Awan,Farrukh,T; Flynn,Joseph,M; Jones,Jeffrey,A; Andritsos,Leslie,A; Maddocks,Kami,J; Sass,Ellen,J; Lucas,Margaret,S; Chase,Weihong; Waymer,Sharon; Ling,Yonghua; Jiang,Yao; Phelps,Mitch,A; Byrd,John,C; Lucas,David,M; Woyach,Jennifer,A. "Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma." LEUKEMIA & LYMPHOMA. Vol. 56, no. 10. (October 2015.): 2834-2840.

Halley,Patrick,D; Lucas,Christopher,R; McWilliams,Emily,M; Webber,Matthew,J; Patton,Randy,A; Kural,Comert; Lucas,David,M; Byrd,John,C; Castro,Carlos,E. "Daunorubicin-Loaded DNA Origami Nanostructures Circumvent Drug-Resistance Mechanisms in a Leukemia Model." SMALL. Vol. 12, no. 3. (January 2016.): 308-320.


Reference Works

January 2000 Marcucci G, Bloomfield CD, Balcerzak SP, Korlas PJ, Stanley HR, Fingert H, Maghraby, EA, Lucas, DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Phase I Trial of Genasense (G3139, Genta, Inc.), A BCL-2 Antisense, in Refractory or relapsed Acute Leukemia." . : 513a
January 2001 Marcucci G, Bloomfield CD, Balcerzak SP, Fingert H, Maghraby EA, Kourlas P, Lucas, DM, Chen KK, Byrd JC, Kraut EH, Grever MR, Caligiuri MA."Biologic Activity of G3139 (Genasense), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia" . : 1149
January 2001 Bannerji R, Kitada S, Flinn IW, Pearson M, Lucas, DM, Grever MR, Reed JC, Byrd JC."Campath-1H Antibody Induces Transmembrane Signaling in vitro and in vivo in Patients with Chronic Lymphocytic Leukemia and Promotes Tumor Clearance in Part Through Caspase mediated Apoptosis" . : 808a
January 2001 Bannerji R, Flinn IW, Pearson M, Shinn C, Sickler J, Lucas M,Lucas, DM Byrd JC."Campath-1H Antibody Induces Transmembrane Signaling in Vivo in Patients with Chronic Lymphocytic Leukemia (CLL) and Promotes Tumor Clearance via a Caspase-9 Apoptotic Pathway" . : 1215a
January 2001 Baird ME, Lucas, DM, Mone AP, Waymer S, Warrell RP, Byrd JC, Grever MR."G3139 Promotes Release of IL-8 by Chronic Lymphocytic Leukemia Cells Cultured in vitro: Potential Implications for Therapeutic Use" . : 218b
January 2001 Aron JL, Murphy T, Parthun MR, Bannerji R, Kanakry C, Lucas, DM, Flinn IW, Marcucci G, Grever MR, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide (FR901228) Induces Apoptosis Via Activation of the Caspase 8 Pathway Concurrent with Lysine Specific Acetylation in Chronic Lymphocytic Leukemia Cells" . : 807a
January 2001 Marcucci G, Byrd JC, Cataland SR, Fisher DB, Lucas, DM, Chan KK, Klisovic M, Young DC, Didier LA, Balcerzak SP, Frankel SR, Kraut EH, Bloomfield CD, Grever MR, Caligiuri MA."Clinical and Biological Activity of Genasense (G3139, Genta, Inc.), a BCL-2 Antisense, in Refractory or Relapsed Acute Leukemia: A Phase I Study" . : 216b
January 2001 Lucas, DM Baird ME, Neuberg DS, Tallman MS, Flinn IW, Byrd JC, Grever MR."Importance of Culture Conditions for in vitro Chemosensitivity Assessment in Chronic Lymphocytic Leukemia Cells: Preliminary Results From Laboratory Studies, Eastern Cooperative Oncology Group Study 2997" . : 284b
January 2002 Lucas, DM, Davis ME, Parthun MR, Mojica RC, Mone AP, Zwiesler J, Byrd JC, Grever MR."MS-275 Promotes Apoptosis in Cells from Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Concurrent with Inhibition of Histone Deactylase." . : 1500a
January 2002 Pavletic SZ, Bociek G, Foran, J, Hatcher L, Rubocki R, Kuszynsky, C, Lucas, DM, Grever MR, Hock L, Joshi S. Hardiman P, Bierman P, Vose J, Armitage J, Talmage J."Immunological Effects of Pentostatin in a Minimally Myelosuppressive Regimen for Allogeneic Stem Cell Transplantation" . : 2446a
January 2002 Mone AP, Lucas, DM, Aron JL, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green Je, Grever MR, Byrd JC."HU1D10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia Cells: Justification for Combination Studies of Hu1D10 with P13 Kinase Inhibitors" . : 1496a
January 2002 Lucas, DM, Parthun MR, Mojica RD, Mone AP, Byrd JC, Grever MR."MS-275 Reduces Viability and Induces Changes in Histone Acetylaton in Cells From Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)." .
January 2002 Lucas, DM, Baird ME, Byrd JC, Tschumper RC, Jelinek DF, Kitada S, Reed JC, Rosenwald A, Staudt LM, Neuberg DS, Tallman MS, Flinn IW, Grever MR."ZAP70 and Caspase-3 Protein Expression Independently Associate with Immunoglobulin VH Gene Mutational Status in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)" . : 3168a
January 2002 Lin TS, Flinn IW, Lucas MS, Sickler J, Moran ME, Porcu P, Lucas, DM, Grever MR, Byrd JC."Filgrastim and Alemtuzumab (Campath-1H) for Refractory Chronic Lymphocytic Leukemia: High Frequency of Cytomegalovirus Disease and Delayed Neutropenia" . : 3168a
January 2002 Dewald GW, Paietta E, Goloubeva O, Bennett JM, Brockman SR, Paternoster SF, Lucas, DM, Neuberg DS, Flinn I, Tallman M, Grever MR, Byrd JC."Correlation of Interphase Fluorescence In Situ Hybridization (FISH) Abnomalies with Cell Morphology and Immunophenotyping in Chronic Lymphocytic Leukemia (B-CLL)." . : 2334a
January 2003 Lucas, DM, Zhang L, Freitas MA, Wickham J, Parthun MR, Davis ME, Marcucci G, Byrd JC, Grever MR."MS-275 Mediated Apoptosis and Generation of Reactive Oxygen Species Are Caspase Dependent in B-Cell Chronic Lymphocytic Leukemia (CLL)." . : 1566a
January 2003 Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas, DM, Byrd JC."Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL)." . : 1594a
January 2003 Marcucci G, Stock W, Zwiebel JA, Cataland SR, Dai F, Moran M, Lucas, DM, Liu S, Klisovic MI, Kefauver C, Green M, Chan KK, Frankel SR, Grever MR, Byrd JC."Clinical Activity of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)" . : 1398a
January 2003 Marcucci G, Dai G, Klisovic MI, Shen T, Liu S, Sher DA, Lucas, DM, Whitman SP, Vukosavljevic T, Zwiebel JA, Frankel SR, Grever MR, Stock W, Chan KK, Byrd JC."Pharmacologic and Biologic Assessment of Genasense (GNS, Oblimersen Sodium), a Pro-Apoptotic to Bcl-2 Oligonucleotide, in Combination with Daunorubicin and Cytarabine: A Phase I Study in Previously Untreated Elderly Acute Myeloid Leukemia (AML)." . : 3254a
January 2004 Lucas, DM, Zhang L, Davis ME, Su X, Sklenar A, Parthun MR, Freitas MA, Kitada S, Reed JC, Marcucci G, Grever MR, Byrd JC."The Histone Deacetylase Inhibitor Depsipeptide Mediates Distinct Patterns of Histone Acetylation in Cells Overexpressing Bcl-2." . : 2802a
January 2004 Byrd JC, Lin TS, Dalton JT, Wu D, Fischer B, Moran ME, Blum KA, Shank RS, Lucas, DM, Lucas MS, Suarez J-R, Grever MR."Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL)" . : 341a
January 2004 Byrd JC, Gribben JG, Peterson B, Grever MR, Lozanski G, Lucas, DM, Larson RA, Caligiuri MA, Heerema NA."Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy" . : 476a
January 2004 Motiwala T, Ghoshal K, Majumder S, Kutay H, Neuberg DS, Kitada S, Reed JC, Dewald GW, Flinn IW, Tallman MA, Liu T, Plass C, Lucas, DM, Byrd JC, Jacob ST, Grever MR."Methylation of the Tumor Suppressor Gene PTPRO (Receptor-Type Protein Tyrosine Phosphatase) Is Associated with Expression of Important Apoptosis-Related Proteins in Chronic Lymphocytic Leukemia (CLL)." . : 2804a
January 2004 Grever MR, Lucas, DM, Dewald GW, Neuberg DS, Flinn IW, Tallman MS, Gribben JG, Byrd JC."Outcome of Treatment with Fludarabine Versus Fludarabine and Cyclophosphamide in Chronic Lymphocytic Leukemia (CLL) Is Adversely Impacted by High Risk Genetic Features: Results from ECOG 2997" . : 3487a
January 2004 Lucas, DM, Dewald GW, Neuberg DS, Byrd JC, Lozanski G, Harbison J, Cunningham KD, Flinn IW, Tallman MS, Grever MR."Clinical, Laboratory, and Treatment Outcome Characteristics of Chronic Lymphocytic Leukemia (CLL) Patients with p53 Mutations or del(17p) Enrolled on a Prospective Phase III Clinical Trial: Short Progression Free Survival, Irrespective of Fludarabine-Base" . : 949a
January 2004 Lin TS, Heerema NA, Swenor J, Lucas MS, Moran ME, Cheney CM, Lucas, DM, Young D, Caligiuri MA, Grever MR, Byrd JC."A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities" . : 3469a
January 2004 Lin TS, Fischer B, Moran ME, Lucas, DM, Shank RS, Kraut EH, Farag SS, Lucas MS, Colevas AD, Grever MR, Byrd JC.."Phase I Dose Escalation Study of Flavopiridol in Combination with Fludarabine and Rituximab: Activity in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma" . : 2492a
January 2004 Lin TS, Biswas S, Naumovski L, Lecane P, Lucas MS, Moran ME, Mone AP,Lucas, DM."Phan S-C, Miller RA, Byrd, JC. Effects of the Redox Mediator Motexafin Gadolinium in a Pilot Phase I Trial in Refractory Chronic Lymphocytic Leukemia (CLL)." . : 3486a
January 2004 Kitada S, Reed JC, Lucas, DMLucas DM, Neuberg DS, Gribben JG, Dewald GW, Flinn IW, Tallman MS, Byrd JC, Michael R. Grever MR.."Critical Molecular Studies to Strategically Plan Therapy in Chronic Lymphocytic Leukemia (CLL): Correlating Cellular Proteins with Defined Prognostic Patient Subsets and Their Response to Treatment." . : 956a
January 2005 Johnson AJ, Edwards R, Smith LL, Lucas, DM, Croce CM, Muthusamy N, Chen C-S, Liu Z, Chan KK, Grever MR, Byrd JC."The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia" . : 51a
January 2006 Lin TS, Lucas MS, Heerema NA, Matkovich JA, Moran ME, Cheney C, Lucas, DM, Young DC, Caligiuri MA, Grever MR, Byrd JC."A Phase II Study of the TNF- Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities" . : 2841a
January 2006 Johnson AJ, Wagner AJ, Smith LL,Lucas, DM, DeLay MD, Allison JM, Ivy SP, Lin TS, Byrd JC."The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL" . : 2101a
January 2006 Lucas, DM, Hussain S-R A, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SK, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR."Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells" . : 2098a
January 2006 Edwards RB, Lucas, DM, Lozanski G, Johnson AJ, Su B-N, Lin TS, Byrd JC, Kinghorn AD, Grever MR."Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells" . : 2600a
January 2006 Browning RE,Lucas, DM, Geyer SM, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC."Expression of Tcl-1 as a Potential Prognostic Factor for Treatment Outcome in B-Cell Chronic Lymphocytic Leukemia" . : 2792a
January 2007 Lucas, DM, Edwards RB, DeLay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD, Grever MR."The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL" . : 3123a
January 2007 West DA, Lucas, DM, Davis ME, DeLay MD, Johnson AJ, Guster SK, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, Byrd JC."The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia" . : 2101a
January 2007 DeLay MD, Johnson AJ, Lucas, DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR, Byrd JC."Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia" . : 3095a
January 2008 Blum KA, Liu Z, Lucas, DM, Baiocchi RA, Lin TS, Benson D, Devine SM, Jones J, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC.."A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation." . : 3169a
January 2008 Hertlein E, West DA, Craig RW, Lucas, DM, Byrd JC."NF- B Is Active in Mcl-1 Promoter Regulation in Human CLL" . : 2625a
January 2008 Alinari L, Hertlein E, Goldenberg DM, Lapalombella R, Yan F, Zhang X, Lucas, DM, Muthusamy N, Byrd JC, Baiocchi RA.."Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma" . : 886a
January 2009 Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas, DM, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC."The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia" . : 886a
January 2009 Hertlein E, Triantafillou G, Hessler J, Zhang X, Jarjoura D, Lucas, DM, Lee RJ, Muthusamy N, Goldenberg DM, Byrd JC."Immunoliposomes Incorporated with Humanized Monoclonal Antibody, Milatuzumab, Induce Cell Death in CLL by Retention of the CD74 Receptor On the Surface of B Cells" . : 721a
January 2009 Lucas, DM, Sass EJ, Edwards RB, Pan L, Lozanski G, Heerema NA, Byrd JC, Kinghorn AD, Grever MR.."Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression" . : 1737a
December 2010 Smith MR, Neuberg D, Flinn IW, Grever MR, Bennett JM, Dewald G, Paietta EM, Litzow MR, Rowe JM, Lucas, DM, Kitada S, Jelinek DF, Gribben JG, Byrd JC, Reed JC, Hussein MA, Appelbaum FR, Larson RA, Moore Jr DF, Tallman MS."Increased Incidence of Therapy Related Myeloid Neoplasia (t-MN) After Initial Therapy for CLL with Fludarabine-Cyclophosphamide (FC) Vs Fludarabine (F): Long-Term Follow-up of US Intergroup Study E2997" Orlando. : 924
December 2010 Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones JA, Flynn JM, Lucas, DM, Grever MR, Byrd JC."Autophagy Is a Relevant Cellular Process In CLL and Contributes to Drug Resistance of Flavopiridol." Orlando. : 691
December 2010 Hertlein EK, Yu L, Zhang J, Johnson AJ, Lucas, DM, Marcucci G, Jarjoura D, Byrd JC."Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-κB Signaling Pathway In Disease" Orlando. : 3642
December 2011 Gupta SV, Hertlein EK, Woyach JA, Sass EJ, Davis ME, Byrd JC, Lucas DM.Lucas, DM."The Novel Proteasome Inhibitor Carfilzomib Functions Independently of p53 to Induce Potent Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells and a Defective NF- B Response" San Diego.
April 2011 Alachkar H, Liu S, Schwind S, Becker H, Metzeler KH, Hickey C, Pang J, Whitman SP, Chan KK, Garzon R, Lucas DM, Perrotti D, Wu L-C, Grever MR, Kinghorn AD, Marcucci G.."The natural oridyct silvestrol decreases oncogenic FLT3 and miR-155 levels in FLT3-ITD positive Acute Myeloid Leukemia (AML) cells" Orlando.
July 2011 Lucas, DM, Lapo Alinari, John T. Patton, A. Douglas Kinghorn, Robert A. Baiocchi, Michael R. Grever."The Protein Synthesis Inhibitor Silvestrol Has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies" Washington.
December 2011 Patton JT, Lustberg ME, Garman SL, Kinghorn AD, Pan L, Lucas, DM, Grever MR, Baiocchi RA."Silvestrol Modulates Direct Anti-Tumor Activity Against Epstein-Barr Virus (EBV)-Associated Lymphomas While Sparing Innate and Antigen Specific Adaptive Immunity" San Diego.
July 2011 Gupta SV, Sass EJ, Davis ME, Edwards RB, Lozanski G, Heerema NA, Lehman A, Zhang X, Jarjoura D, Byrd JC, Chan KK, Kinghorn AD, Grever MR, Phelps MA, Lucas, DM."Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin" Chicago.
December 2011 Alinari L, Edwards RB, Prince CJ, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA, Lucas, DM."Targeting the Cyclin D - CDK4/6 - Rb Axis in Mantle Cell Lymphoma with the Novel Translation Inhibitor Silvestrol." San Diego.
December 2011 Alachkar H, Santhanam R, Lucas, DM, Schwind S, Hickey C, Pang J, Perrotti D, Pan L, Kinghorn AD, Marcucci G, Grever MR.."Translational Research From the Tropical Forest: Silvestrol, a Natural Product From the Plant Aglaia Foveolata inhibits the Expression of Tyrosine Kinases and Shows a Significant In Vivo Activity in Acute Myeloid Leukemia (AML)." San Diego.
May 2011 Kogure, T; Braconi, C; Lucas, DM; Grever, M; Kinghorn, AD; Patel, T."Therapeutic Efficacy of Silvestrol, a Novel Protein Translation Inhibitor, as an Anticancer Agent for Cholangiocarcinoma" . : S913
December 2012 Hertlein EK, Chen TL, Claus R, Plass C, Lehman A, Jarjoura D, Maddocks K, Jones JA, Lucas DM, . Johnson AJ, Byrd JC."The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia" San Diego.
December 2012 Claus R, Ruppert AS, Lucas DM, Zucknick M, Rassenti LZ, Greaves A, Neuberg DC, Wierda WG, Keating MJ, Brown JR, Gribben JG, Rai KR, Grever MR, Kay NE, Kipps MJ, Plass C, Byrd JC."The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set." San Diego.
December 2013 Patton JT, Hartlage AS, Pan L, Lustberg ME, Drohan CM, Martin MF, Kinghorn AD, Caligiuri MA, Grever MR, Lucas DM, Baiocchi RA.". Silvestrol Modulates Indirect Anti-Tumor Activity and Potentiates Immune Response To Epstein-Barr Virus-Driven Lymphoproliferative Disease" San Diego.
October 2013 Woyach JA, Flynn JM, Jones JA, Andritsos LA, Lucas M, Chase W, Yang Y, Lucas DM, Sass E, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC.". Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)" San Francisco.
December 2014 Brooks C, Chen J, Lucas DM, Muthusamy N, Bergstein I, Rowinsky E."SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (IL-3R), Shows Cytotoxic Activity Against Hairy Cell Leukemia" San Diego.
December 2014 Patton JT, Mitchell ML, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA.". Identifying and Targeting Cytotoxic Tumor-Associated Macrophages in Epstein-Barr Virus-Driven Lymphoproliferative" San Diego.
Miller CR, Ruppert AS, Coombes K, Lehman AM, Blachly JS, Lucas DM, Grever MR, Tallman MS, Flinn IW, Rassenti LZ, Kipps TJ, Sampath D, Byrd JC, Hertlein EK."The Aberrantly Expressed Long Noncoding RNA, TRERNA1, Predicts for Aggressive Disease in Chronic Lymphocytic Leukemia" .
Tsai YT, Lozanski G, Lehman AM, Sass E, Hertlein EK, Salunke S, Chen CS, Grever MR, Byrd JC, Lucas DM.."BRAFV600E Induces ABCB1/P-Glycoprotein Expression and Drug Resistance in B-Cells Via AP-1 Activation" .
Mitchell S, Orwick S, Cannon M, Goettl VM, LaFollette TD, Baloglu E, Senapedis W, Walker AR, Bhatnagar B, Mims AS, Klisovic RB, Vasu S, Blum W, Lucas DM, Blachly JS, Garzon R, Bloomfield CD, Lapalombella R, Byrd JC."In Vitro and In Vivo Anti-Leukemic Effects of KPT-9274, a Reported PAK4 Allosteric Modulator, in Acute Myeloid Leukemia: Promising Results Justifying Further Development in This Disease" .
Hing ZA, Fung HYJ, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith JL, Yu X, Meng X, Sun Q, Cagatay T, MacMillan JB, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman M, Byrd JC, Chook YM, Garzon R, Lapalombella R.."Next Generation XPO1 Inhibitor Shows Improved Efficacy and In Vivo Tolerability in Hematologic Malignancies" .
Hertlein EK, Chen TL, Lucas DM, Gupta N, MacMurray J, Goettl VM, Lehman AM, Johnson AJ, Byrd JC."NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia" .

Inventions and Patents

Lucas DM, Parthun MR, Byrd JC, Grever MR. "Treatment of Patients with Chronic Lymphocytic Leukemia." Issued 2005, (patent granted), and Patent No. 6841565 B1

Byrd JC, Johnson Aj, Mahoney E, Lucas DM, Grever MR. "Compositions and Methods for Increasing Drug Efficacy in Cancer." filed 2011, (patent pending), and Application No. PCT US2011 059645

Baiocchi, Robert; Patton, John; Lucas, DM; Grever, Michael; 'Douglas Kinghorn'. "“Immune Modulatory Properties of Silverstrol”." filed 2011,



"The Protein Synthesis Inhibitor Silvestrol has In Vitro and In Vivo Efficacy in Aggressive B-cell Malignancies." Presented at NCI Translational Science Meeting, Washington, DC. (July 2011)


Professional Activities

present Lab Tour and Presentation with Congresswoman Kilroy's Legislative Team. OSU Office of Government Affairs.
present OSUWMC Trainee Research Day.
2010 - present Light the Night. Leukemia & Lymphoma Society.
2012 - present American Cancer Society Seed Grant. American Cancer Society.
2012 - present Pennies for Patients. Leukemia & Lymphoma Society.
2010 Pelotonia. OSUCCC/James Cancer Hospital.